FIELD: biotechnology.
SUBSTANCE: antibody specifically binding to PTK7 (human protein tyrosine kinase 7), as well as a conjugate of the said antibody with a cytotoxic agent, is claimed. Nucleic acids encoding the antibody are also provided and include expression vectors and host cells. In addition, methods for application of the said antibody, including conjugate, for cancer diagnosis and treatment are provided.
EFFECT: effective targeting of tumour stem cells, which can be used to treat patients suffering from a wide range of malignant tumours.
52 cl, 42 dwg, 5 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| NOVEL MODULATORS AND METHODS FOR USE THEREOF | 2011 |
|
RU2592672C9 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| ANTI-SEZ6 ANTIBODIES AND METHODS FOR USING THEM | 2013 |
|
RU2691698C2 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| USE OF O-ACETYLATED GD2 GANGLIOSIDE AS TARGET AS NOVEL THERAPEUTIC AND DIAGNOSTIC APPROACH IN MALIGNANT GROWTHS CONTAINING TUMOUR STEM CELLS | 2014 |
|
RU2702428C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
